Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 10/20 | 1.00 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 10/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758460 | 1.00 | CES1 (1.00) | CES1DNMT1TGM2HTR6 | |
| SCHEMBL8873852 | 0.94 | CES1 (0.88) | CES1DNMT1TGM2HTR6 | |
| SCHEMBL8872450 | 0.82 | CES1 (0.69) | CES1DNMT1TGM2HTR6 | |
| SCHEMBL8872444 | 0.82 | CES1 (0.69) | CES1DNMT1TGM2HTR6 | |
| SCHEMBL1398043 | 0.82 | CES1 (0.69) | CES1DNMT1TGM2 | |
| SCHEMBL6176815 | 0.82 | CES1 (0.69) | CES1DNMT1TGM2HTR6 | |
| SCHEMBL8573750 | 0.82 | CES1 (0.69) | CES1DNMT1TGM2 | |
| SCHEMBL7054754 | 0.80 | CES1 (0.66) | CES1DNMT1TGM2HTR6 | |
| SCHEMBL7054752 | 0.80 | CES1 (0.66) | CES1DNMT1TGM2HTR6 | |
| SCHEMBL7052297 | 0.80 | CES1 (0.66) | CES1DNMT1TGM2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118125961-A | 1- (4-Trifluoromethyl-benzyl) -isatin derivative and preparation method and application thereof | 武汉大学人民医院（湖北省人民医院） | 2024-06-04 | — | — | CN | disclosed |
| CN-114805353-B | Synthesis of azatryptanthrin derivative and application of azatryptanthrin derivative in prevention and treatment of plant pathogenic bacteria, fungi bactericide and anti-plant virus preparation | 贵州大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-114805353-A | Synthesis of azatryptanthrin derivative and application of azatryptanthrin derivative in prevention and treatment of plant pathogenic bacteria, fungi bactericide and anti-plant virus preparation | 贵州大学 | 2022-07-29 | — | — | CN | disclosed |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-9889130-B2 | Substituted 3-benzofuranyl-indol-2-one-3-acetamididopiperazine derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2018-02-13 | — | — | US | disclosed |
| US-20170119761-A1 | SUBSTITUTED 3-BENZOFURANYL-INDOL-2-ONE-3-ACETAMIDIDOPIPERAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2017-05-04 | — | — | US | disclosed |
| CN-102361864-B | 3-benzofuryl-indol-2-one-3-kharophen the bridged piperazine derivatives replaced, its preparation and therepic use thereof | SAI NUOFEI (FR) | 2015-11-25 | — | — | CN | disclosed |
| CN-102361865-B | At 3-benzofuryl-indol-2-one derivates that 3 replace, its preparation and therepic use thereof | SAI NUOFEI (FR) | 2015-11-25 | — | — | CN | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-5599814-A | SUBSTITUTED PYRIDAZINO(4,5-B)QUINOLINES AS ANTAGONISTS OF EXCITATORY AMINO ACIDS | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1997-02-04 | — | — | US | disclosed |
| US-5597922-A | Glycine receptor antagonist pharmacophore | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0747354-A1 | 3-Substituted oxindole derivatives as potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0516297-B1 | Pyridazinediones and their use in the treatment of neurological disorders | ZENECA LTD (GB) | 1996-10-30 | — | — | EP | disclosed |
| US-5565483-A | ADMINISTERING AS THERAPY FOR ISCHEMIA, CONVULSIONS OR ASTHMA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996004288-A1 | GLYCINE RECEPTOR ANTAGONIST PHARMACOPHORE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0516297-A1 | Pyridazinediones and their use in the treatment of neurological disorders | ZENECA LIMITED (GB) | 1992-12-02 | — | — | EP | disclosed |
| US-4883800-A | DIABETES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-11-28 | — | — | US | disclosed |
| US-4734419-A | Quinazoline derivatives, compositions thereof and their use in treating diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| EP-0218999-A2 | New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119761-A1 | SUBSTITUTED 3-BENZOFURANYL-INDOL-2-ONE-3-ACETAMIDIDOPIPERAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | IDO1, TPH1, QDPR | CES1 2257/4885DNMT1 3180/4885TGM2 4356/4885 |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | CES1 1494/4885DNMT1 1912/4885TGM2 421/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | CES1 1494/4885DNMT1 1912/4885TGM2 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.